VK2735 (Oral)

About viking-therapeutics

Viking Therapeutics is a US-based, publicly-traded biotech focused on developing innovative small-molecule drugs for metabolic diseases. Its core achievement is advancing VK2735, a dual GLP-1/GIP agonist, into a Phase 3 obesity program with both subcutaneous and oral formulations, demonstrating significant weight loss in mid-stage trials. The company's strategy leverages deep expertise in hormone receptor pharmacology to create differentiated therapies with potential advantages over existing incretin-based treatments. With a market cap of approximately $3.63 billion, Viking has captured substantial investor interest as a key player in the next generation of obesity therapeutics.

Therapeutic Areas